Trending...
- Attn: Newspapers: EXTRA! EXTRA! Read all about it! Get in on Giant New Advertising Revenues NOW!
- PR Support That Cuts the Mustard for Busy Founders
- California: Governor Newsom announces appointments 12.30.2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees.
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, December 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on The Californer
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
More on The Californer
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, December 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on The Californer
- Victoria Carson's Album "Glow" Dropped New Year's Day!
- Inkdnylon Launches Bilingual Ask Inkdnylon Platform
- Annotatable AI Redefines Web Interaction with the World's Most Powerful AI-Driven Web Annotations
- ezPaycheck 2026 Simplifies Qualified Tip Payroll for Restaurants
- DeliverySoCal.com Launches Free Delivery Driver Pay Calculator to Help Gig Workers Track Earnings
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
More on The Californer
- Domenic Migliore Releases New Short Story Collection, Frame Story
- JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
- Airiodion Group Named a Top Boutique Change Management Consulting Firm
- ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
- Cheap Car Wash Near California State University Northridge
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Filed Under: Business
0 Comments
Latest on The Californer
- California: Federal court finally ends illegal federalization of National Guard after Trump gives up, Governor Newsom directs leadership to quickly send soldiers home to families
- NUEVO EN 2026: Leyes de California que entran en vigencia en el nuevo año
- NEW IN 2026: California laws taking effect in the new year
- Glossa Launches Slack Integration to Capture Requirements Where Teams Work
- PowerTribe Releases New Heavy Metal Single "The Earthlings Have Died"
- California: Following LA fires, Governor Newsom extends key provision to fast‑track wildfire safety window, protecting more communities across the state
- Australian Soulstress NARDIA returns to the U.S. for her January 2026 Tour
- California advances Jobs First agenda, expands career pathways and worker protections statewide
- EDCAPIT Reports 2025 Results: From Zero to a Global AI-Powered EdTech Platform
- HIGHTITAN Trading Center Optimizes Server Architecture and Load Management
- Mystery Enterprises Completes Testing Phase for Four Fully Automated Murder Mystery Games
- Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®
- Governor Newsom prepositions emergency resources in Southern California ahead of New Year's Storm
- California: Governor Newsom announces appointments 12.30.2025
- Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL)
- AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
- IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever
- Long Beach Health Department Reaffirms Commitment to Infant Hepatitis B Protection
- Critical Reach Unveils Initiative to Equip Every U.S. School with Crisis Technology at No Cost
- Are You Hiring The Right Heater Repair Company in Philly?